Comparative study of whole-body MRI and bone scintigraphy for the detection of bone metastases

Balliu, E.; Boada, María José; Peláez, Isabel María Gámez; Vilanova, Joan C.; Barceló‐Vidal, C.; Rubio, A M Martín; Galofré, Pere; Castro, A.; Pedraza, Salvador

doi:10.1016/j.crad.2010.07.002

Cited by 32 publications

(17 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, false-positive findings are frequently seen in degenerative changes, inflammation, and trauma [9]. New methods with higher accuracy are worth discussing because the suboptimal specificity and sensitivity of bone scintigraphy are concerning [10,11].…”

mentioning

confidence: 99%

Whole-Body Diffusion-Weighted MRI Compared With ¹⁸F-NaF PET/CT for Detection of Bone Metastases in Patients With High-Risk Prostate Carcinoma

Mosavi

Johansson

Sandberg

et al. 2012

American Journal of Roentgenology

105

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Whole-Body Diffusion-Weighted MRI Compared With ¹⁸F-NaF PET/CT for Detection of Bone Metastases in Patients With High-Risk Prostate Carcinoma

Mosavi

Johansson

Sandberg

et al. 2012

American Journal of Roentgenology

105

View full text Add to dashboard Cite

show abstract

“…MRI is more sensitive at detecting early bone marrow lesions than CT. Comparative studies have indicated that MRI is more sensitive and specific than pBS (14)(15)(16)(17).…”

mentioning

confidence: 99%

A Prospective Study Comparing ^99mTc-Hydroxyethylene-Diphosphonate Planar Bone Scintigraphy and Whole-Body SPECT/CT with ¹⁸F-Fluoride PET/CT and ¹⁸F-Fluoride PET/MRI for Diagnosing Bone Metastases

et al. 2017

View full text Add to dashboard Cite

See an invited perspective on this article on page 1776.We prospectively evaluated and compared the diagnostic performance of 99m Tc-hydroxyethylene-diphosphonate ( 99m Tc-HDP) planar bone scintigraphy (pBS), 99m Tc-HDP SPECT/CT, 18 F-NaF PET/CT, and 18 F-NaF PET/MRI for the detection of bone metastases. Methods: One hundred seventeen patients with histologically proven malignancy referred for clinical pBS were prospectively enrolled. pBS and whole-body SPECT/CT were performed followed by 18 F-NaF PET/CT within 9 d. 18 F-NaF PET/MRI was also performed in 46 patients. Results: Bone metastases were confirmed in 16 patients and excluded in 101, which was lower than expected. The number of equivocal scans was significantly higher for pBS than for SPECT/CT and PET/CT (18 vs. 5 and 6, respectively; P 5 0.004 and 0.01, respectively). When equivocal readings were excluded, no statistically significant difference in sensitivity, specificity, positive predictive value, negative predictive value, or overall accuracy were found when comparing the different imaging techniques. In the per-patient analysis, equivocal scans were either assumed positive for metastases ("pessimistic analysis") or assumed negative for metastases ("optimistic analysis"). The percentages of misdiagnosed patients for the pessimistic analysis were 21%, 15%, 9%, and 7% for pBS, SPECT/CT, PET/CT, and PET/MRI, respectively. Corresponding figures for the optimistic analysis were 9%, 12%, 5%, and 7%. In those patients identified as having bone metastases according to the reference standard, SPECT/CT, 18 F-NaF PET/CT, and PET/MRI detected additional lesions compared with pBS in 31%, 63%, and 71%, respectively. Conclusion: 18 F-NaF PET/CT and whole-body SPECT/CT resulted in a significant reduction of equivocal readings compared with pBS, which implies an improved diagnostic confidence. However, the clinical benefit of using, for example, 18 F-NaF PET/CT or PET/MRI as compared with SPECT/CT and pBS in this patient population with a relatively low prevalence of bone metastases (14%) is likely limited. This conclusion is influenced by the low prevalence of patients with osseous metastases. There may well be significant differences in the sensitivity of SPECT/CT, PET/CT, and PET/MRI compared with pBS, but a larger patient population or a patient population with a higher prevalence of bone metastases would have to be studied to demonstrate this.

show abstract

“…Based on its wide availability, limited cost, and sensitivities and specificities that have been considered acceptable for several decades, BS has been and still remains commonly used for the detection of bone lesions in ''osteophilic'' cancers (breast, prostate, thyroid, kidney… (Avrahami et al 1989;Balliu et al 2010;Gosfield et al 1993). Curative therapy may indeed only be considered if no metastasis is present; if metastases are present, systemic treatment is required.…”

Section: Bone Scintigraphy and Single Photon Emission Computed Tomogrmentioning

confidence: 99%

MRI for Response Assessment In Oncologic Bone Marrow Lesions

Lecouvet

Omoumi

Larbi

et al. 2013

Magnetic Resonance Imaging of the Bone Marrow

View full text Add to dashboard Cite

Comparative study of whole-body MRI and bone scintigraphy for the detection of bone metastases

Cited by 32 publications

References 20 publications

Whole-Body Diffusion-Weighted MRI Compared With ¹⁸F-NaF PET/CT for Detection of Bone Metastases in Patients With High-Risk Prostate Carcinoma

Whole-Body Diffusion-Weighted MRI Compared With ¹⁸F-NaF PET/CT for Detection of Bone Metastases in Patients With High-Risk Prostate Carcinoma

A Prospective Study Comparing ^99mTc-Hydroxyethylene-Diphosphonate Planar Bone Scintigraphy and Whole-Body SPECT/CT with ¹⁸F-Fluoride PET/CT and ¹⁸F-Fluoride PET/MRI for Diagnosing Bone Metastases

MRI for Response Assessment In Oncologic Bone Marrow Lesions

Contact Info

Product

Resources

About

Comparative study of whole-body MRI and bone scintigraphy for the detection of bone metastases

Cited by 32 publications

References 20 publications

Whole-Body Diffusion-Weighted MRI Compared With 18F-NaF PET/CT for Detection of Bone Metastases in Patients With High-Risk Prostate Carcinoma

Whole-Body Diffusion-Weighted MRI Compared With 18F-NaF PET/CT for Detection of Bone Metastases in Patients With High-Risk Prostate Carcinoma

A Prospective Study Comparing 99mTc-Hydroxyethylene-Diphosphonate Planar Bone Scintigraphy and Whole-Body SPECT/CT with 18F-Fluoride PET/CT and 18F-Fluoride PET/MRI for Diagnosing Bone Metastases

MRI for Response Assessment In Oncologic Bone Marrow Lesions

Contact Info

Product

Resources

About

Whole-Body Diffusion-Weighted MRI Compared With ¹⁸F-NaF PET/CT for Detection of Bone Metastases in Patients With High-Risk Prostate Carcinoma

Whole-Body Diffusion-Weighted MRI Compared With ¹⁸F-NaF PET/CT for Detection of Bone Metastases in Patients With High-Risk Prostate Carcinoma

A Prospective Study Comparing ^99mTc-Hydroxyethylene-Diphosphonate Planar Bone Scintigraphy and Whole-Body SPECT/CT with ¹⁸F-Fluoride PET/CT and ¹⁸F-Fluoride PET/MRI for Diagnosing Bone Metastases